Floatz logo

Tamoxifen

Breast Neoplasm

Eli Lilly and CompanySmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
65/ 100

Competitive context

174 Active assets in the Breast Neoplasm cohort.

Asset / SponsorPhaseRating
Exemestane
Fujian Cancer Hospital
Phase 4BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 4BB
Adriamycin
Merck Sharp & Dohme LLC
Phase 4BB
Docetaxel
Universitas Airlangga
Phase 4BB
Letrozole
Fujian Cancer Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Tamoxifen is also rated in:

invasive breast carcinomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
breast carcinomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
breast fibroadenomaDormant
BBB
Indicative · Phase 4
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →